Yajie Liu | Cardiac Imaging | Best Researcher Award

Published on by Cardiology and Cardiovascular Medicine

Prof. Dr. Yajie Liu | Cardiac Imaging | Best Researcher Award

Peking University Shenzhen Hospital | China

Author Profile:

Scopus

Orcid

🌟Prof. Dr. Yajie Liu – A Pioneer in Radiation Oncology & Cancer Research Excellence

🎓 EARLY ACADEMIC PURSUITS

Dr. Yajie Liu began her medical journey with a Bachelor of Medicine (1985–1990) from Norman Bethune University of Medical Sciences. Driven by a deep interest in oncology, she completed her Master's degree in Oncology (1993–1996) from Harbin Medical University, followed by a prestigious Ph.D. in Oncology (1998–2001) at the Peking Union Medical College.

To expand her global medical perspective, she completed a Visiting Scholar Fellowship in Radiation Oncology at Chonnam National University Hospital in South Korea in 2010.

🏥 PROFESSIONAL ENDEAVORS

Dr. Liu's medical career spans over three decades of dedicated clinical service and leadership:

  • 1990–1992: Resident Physician, ENT, First Workers' Hospital of Liaohe Petroleum Exploration Bureau

  • 1992–1998: Resident & Attending Physician, Radiation Oncology, The Third Affiliated Hospital of Harbin Medical University

  • 2001–2017: Progressed from Attending to Chief Physician and Deputy Director at Shenzhen People’s Hospital

  • 2017–Present: Chief Physician and Director, Department of Radiation Oncology, Peking University Shenzhen Hospital

Her ascent to leadership reflects a consistent trajectory of clinical excellence and patient-centered care in oncology.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIAC IMAGING

Dr. Liu has led and co-led numerous research projects focused on:

  • Radiosensitization in Cancer Therapy

  • Hyperthermia and Serum Biomarkers

  • Radiation-Induced Brain Injury

  • Gene Assays for Breast Cancer Prognosis

  • Advanced Radiotherapy Strategies for Rectal and Colorectal Cancer

She has actively participated in national-level research, contributing to the Ministry of Science & Technology's high-impact projects on biomarkers and innovative radiotherapy techniques.

💡 RESEARCH FUNDING & PROJECT LEADERSHIP

As Principal Investigator (PI):

  • Shenzhen Science & Technology Bureau (4 Projects)

  • Shenzhen Health Commission (1 Project)

  • International Collaboration Grant (¥500K)

These funded projects demonstrate her innovative approach in blending clinical insight with technological advancement, especially in plasma therapy and hypoxic tumor sensitization.

🌐 PROFESSIONAL LEADERSHIP & ACADEMIC SERVICE

Dr. Liu holds key roles in multiple national and regional medical bodies:

  • Standing Committee Member, CRTOG

  • Committee Member, Radiotherapy Branch, Chinese Medical Doctor Association

  • Vice Chair, Lung Cancer Committee, Guangdong Women Doctors’ Association

  • Director, Radiotherapy Branch, Shenzhen Anti-Cancer Association

  • Council Member, Jiusan Society Shenzhen Chapter

Her positions reflect widespread recognition of her expertise and leadership in oncology.

📚 ACADEMIC CITES & COLLABORATIONS

While specific citation metrics are not provided here, Dr. Liu’s work on biomarkers, 21-gene assays, radiation injury, and colorectal cancer radiosensitization has contributed to national and international collaborations, significantly enriching the literature in radiation oncology.

🌍 IMPACT AND INFLUENCE

Dr. Liu's multidisciplinary research has influenced clinical protocols, improved patient outcomes, and inspired young oncologists across China. Her work on low-temperature plasma in radiosensitization reflects her commitment to cutting-edge translational oncology.

🔮 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Yajie Liu's legacy is marked by:

  • Pioneering radiotherapy techniques

  • Mentoring future oncology leaders

  • Driving forward international research collaborations

Her future direction is expected to focus on precision oncology, AI-guided radiotherapy planning, and expanding patient-centered cancer care models.

📑 NOTABLE PUBLICATIONS

"Supplementing sialic acid analogs overcomes radiotherapy resistance in triple-negative breast cancer by exacerbating ER stress"

Authors: M Yang, D Shi, J Lyu, Y Pan, Y Lyv, X Chen, Y Ouyang, Y Liu, Y Li, L Song
Journal: Redox Biology
Year: 2025

"X-ray-activated nanoscintillators integrated with tumor-associated neutrophils polarization for improved radiotherapy in metastatic colorectal cancer"

Authors: H Li, J Zeng, Q You, M Zhang, Y Shi, X Yang, W Gu, Y Liu, N Hu, Y Wang, X Chen, J Mu
Journal: Biomaterials
Year: 2025

Yan Zhang | Cardiovascular diseases | Best Researcher Award

Published on by Cardiology and Cardiovascular Medicine

Prof. Yan Zhang | Cardiovascular diseases | Best Researcher Award 

Prof. Yan Zhang, Affiliated Hospital,Liaoning University of Traditional Chinese Medicine, China

Prof. Yan Zhang is a distinguished researcher and medical expert at the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, China. With extensive experience in Traditional Chinese Medicine (TCM), her research focuses on integrative medicine, herbal formulations, and their clinical applications. She has contributed significantly to the advancement of TCM through numerous publications and collaborative projects. Prof. Zhang is dedicated to bridging modern medical practices with ancient healing traditions, enhancing patient care and treatment efficacy. Her work plays a crucial role in promoting evidence-based TCM approaches for various health conditions, fostering innovation in holistic healthcare solutions.

AUTHOR PROFILE

Scopus Profile

✨ EARLY ACADEMIC PURSUITS:

Prof. Yan Zhang embarked on an illustrious academic journey in Traditional Chinese Medicine (TCM). His foundational education began at Liaoning College of Traditional Chinese Medicine, where he earned a Bachelor’s Degree in Traditional Chinese Medicine (1978-1983). His keen interest in advancing his expertise led him to pursue a Master’s Degree in Typhoid Fever (1986-1989) from the same institution. Determined to further his knowledge, he obtained a Ph.D. in Internal Medicine (2001-2004) from Beijing University of Chinese Medicine, one of China’s most prestigious institutions for TCM studies.

👩‍🎓 PROFESSIONAL ENDEAVORS:

Prof. Zhang’s professional career spans over four decades, marked by dedication and leadership. His significant roles include:

  • Chief Physician (Since 2012): He has been leading the Cardiopulmonary Department at the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine.
  • Director of the Department of Research (2006-2012): At the same hospital, he oversaw groundbreaking medical research and contributed to numerous advancements in TCM.
  • Director of Internal Medicine (1989-2001): He served as the Director of the Department of Traditional Chinese Medicine Internal Medicine at the Liaoning College of Traditional Chinese Medicine Affiliated Hospital.
  • Early Medical Practice (1983-1986): His career began as a Doctor in the Department of Internal Medicine at Dandong City Traditional Chinese Medicine Hospital.

📚 CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIOVASCULAR DISEASES:

Prof. Zhang is a pioneer in Traditional Chinese Medicine, with a specialized focus on cardiovascular diseases. His research revolves around integrating modern medical techniques with traditional healing practices, making significant strides in the treatment of cardiopulmonary disorders. As an academic leader of China’s national key discipline for cardiovascular research, he has spearheaded numerous studies and projects that have influenced the field profoundly.

He is an expert evaluator for major scientific organizations, including:

  • China’s National Natural Science Foundation Projects
  • China’s National Science and Technology Awards

His contributions have been instrumental in shaping national policies and advancements in TCM research.

🌟 IMPACT AND INFLUENCE:

Prof. Zhang’s influence extends beyond his hospital and university. His expertise has earned him several prestigious accolades, including:

  • Renowned Traditional Chinese Medicine Practitioner of Liaoning Province
  • Outstanding Talent & Expert of Liaoning Province
  • Advanced Scientific and Technological Worker in Liaoning Province
  • Recipient of the Special Allowance of the State Council of China

His mentorship has nurtured numerous doctoral candidates, ensuring that the future of Traditional Chinese Medicine remains in capable hands.

📚 ACADEMIC CITES:

Prof. Zhang’s extensive research and scholarly contributions have been widely cited in various national and international medical journals. His work on cardiovascular health, herbal medicine formulations, and the integration of TCM with modern science has set a benchmark for medical professionals worldwide.

🌟 LEGACY AND FUTURE CONTRIBUTIONS:

Prof. Zhang’s legacy in Traditional Chinese Medicine is monumental. His future contributions aim to:

  • Develop new treatment methodologies that combine Western and Eastern medical practices.
  • Mentor the next generation of TCM practitioners.
  • Influence government health policies for the wider acceptance of TCM in mainstream healthcare.
  • Continue his groundbreaking research on cardiovascular diseases.

As a visionary leader in Traditional Chinese Medicine, Prof. Yan Zhang’s dedication, research, and teachings will continue to shape the medical landscape for generations to come.

✨CONCLUSION:

Prof. Yan Zhang’s dedication to Traditional Chinese Medicine (TCM) continues to shape the future of integrative healthcare. Through her research, clinical expertise, and innovative approaches, she bridges ancient wisdom with modern medical advancements, ensuring better patient outcomes . Her contributions not only enhance TCM’s credibility worldwide but also inspire future generations of practitioners and researchers. With a passion for holistic healing and evidence-based medicine, Prof. Zhang remains a key figure in promoting natural therapies for global health and wellness. Her work stands as a testament to the enduring power of TCM in modern medicine.

TOP NOTABLE PUBLICATION

Mechanism of Ferroptosis in Regulating Chronic Heart Failure and Traditional Chinese Medicine Prevention and Treatment Based on Qi Deficiency and Stagnation: A Review

Journal: Chinese Journal of Experimental Traditional Medical Formulae
Year: 2025

Mengchao Wei | Venous thromboembolism | Best Researcher Award

Published on by Cardiology and Cardiovascular Medicine

Dr. Mengchao Wei | Venous thromboembolism | Best Researcher Award

Dr. Mengchao Wei, Peking Union Medical College Hospital, China

Dr. Mengchao Wei is a physician at Peking Union Medical College Hospital, China, specializing in Urology. He graduated with a Doctor’s degree from Sun Yat-sen University in 2019. Since joining PUMCH in 2021, Dr. Wei has focused on optimizing perioperative management for urologic surgeries. He developed a predictive model for venous thromboembolism risk post-surgery, now integrated into clinical practice. Dr. Wei has published 10 journal articles in SCI and Scopus indexed journals. His research aims to improve patient safety and surgical outcomes, making significant contributions to the field of urologic surgery.

Author Profile

Orcid Profile

📚Early Academic Pursuits: 

Dr. Mengchao Wei graduated with a Doctor’s degree from Sun Yat-sen University in 2019. His academic journey laid the foundation for his current work, particularly in the field of Urology, where he became deeply involved in understanding the nuances of perioperative management in urologic surgeries. His comprehensive training and early research set him on a path to clinical excellence and innovation.

⚕️Professional Endeavors and Contributions: 

Since 2021, Dr. Wei has been practicing as a Physician at Peking Union Medical College Hospital, where his focus lies in the optimization of perioperative management in urologic surgeries. His clinical work has had a direct impact on improving patient care and the efficiency of surgical outcomes. Dr. Wei’s contributions include the development of a predictive model for venous thromboembolism risk following urologic surgeries, which has been implemented in real-world clinical practice to enhance patient safety.

🔬Research Focus and Innovations on Venous thromboembolism:

Dr. Wei’s research centers on perioperative management within urology, particularly concerning venous thromboembolism (VTE) risk. His predictive model for VTE risk, now utilized in clinical settings, showcases his ability to translate research into tangible, life-saving outcomes. While his citation index stands at 10, his work continues to gain attention in the medical community. He has published 10 journals in esteemed databases such as SCI and Scopus, reinforcing his status as a respected figure in urologic research.

🌍Impact and Influence: 

Dr. Wei’s contributions have not only benefited his hospital but also shaped the way urologic surgeries are managed perioperatively. By providing a tool that enhances clinical decision-making, he directly improves surgical outcomes, patient safety, and overall healthcare efficiency. His work has influenced peers, setting a new standard in the field of urology.

📑Academic Citations:

Dr. Wei has an impressive citation index of 10, a reflection of the growing recognition of his work and the clinical value it brings. His research continues to receive acknowledgment in relevant medical journals, contributing to the advancement of perioperative care in urology.

🚀Legacy and Future Contributions: 

Dr. Wei’s research and innovations indicate a promising future in the field of urology. He is committed to enhancing perioperative management for urologic surgeries and advancing clinical practices. Moving forward, his aim is to refine predictive models and further contribute to patient safety and surgical excellence.

🌟Conclusion:

Dr. Mengchao Wei’s work at Peking Union Medical College Hospital has made a significant impact on perioperative management in urologic surgeries. His predictive model for venous thromboembolism risk has been successfully integrated into clinical practice, improving patient outcomes and safety. With 10 journal publications in SCI and Scopus indexed journals, Dr. Wei is recognized as a dedicated and innovative physician. His contributions are shaping the future of urologic surgery. As he continues to push the boundaries of medical research, his work promises to enhance the quality of care and patient safety worldwide.

Top Notable Publications 

A nomogram predicting the risk of venous thromboembolism in patients following urologic surgeries

Authors: Mengchao Wei

Journal: Scientific Reports

Year: 2025

The role of antimicrobial prophylaxis in laparoscopic nephrectomy for renal cell carcinoma

Authors: Mengchao Wei

Journal: BMC Urology

Year: 2024

Comparison of AirSeal versus conventional insufflation system for retroperitoneal robot-assisted laparoscopic partial nephrectomy: a randomized controlled trial

Authors: Mengchao Wei

Journal: World Journal of Urology

Year: 2024

Surgery or external beam radiation for solitary small hepatocellular carcinoma

Authors: Mengchao Wei

Journal: Journal of Cancer Research and Therapeutics

Year: 2023

Adjuvant Sorafenib Following Radiofrequency Ablation for Early-Stage Recurrent Hepatocellular Carcinoma With Microvascular Invasion at the Initial Hepatectomy

Authors: Mengchao Wei

Journal: Frontiers in Oncology

Year: 2022

Role of Preoperational Imaging Traits for Guiding Treatment in Single ≤ 5 cm Hepatocellular Carcinoma

Authors: Mengchao Wei

Journal: Annals of Surgical Oncology

Year: 2022

The Combination of Radiation Therapy and Immunotherapy Is Effective and Well-Tolerated for Unresectable Biliary Tract Cancer

Authors: Mengchao Wei

Journal: International Journal of Radiation Oncology, Biology, Physics

Year: 2022

Prognostic Role of Time to Surgery in Hepatocellular Carcinoma at Barcelona Clinic Liver Cancer Stage 0-A

Authors: Mengchao Wei

Journal: Annals of Surgical Oncology

Year: 2020

Radiofrequency ablation plus nucleotide analogues for hepatitis B virus-related hepatocellular carcinoma: a cost-effectiveness analysis

Authors: Mengchao Wei

Journal: American Journal of Translational Research

Year: 2018

Sorafenib versus Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

Authors: Mengchao Wei

Journal: BMC Cancer

Year: 2018

Xingang Li | harmacology | Best Research Article Award

Published on by Cardiology and Cardiovascular Medicine

Prof. Xingang Li | pharmacology | Best Research Article Award 

Prof. Xingang Li, Department of Pharmacy, Beijing Friendship Hospital, China

Prof. Xingang Li is the Deputy Director of the Pharmacy Department at Beijing Friendship Hospital, China, where he also serves as a Chief Pharmacist, Professor, and Ph.D. Supervisor. An expert in quantitative pharmacology and genetic pharmacology, Prof. Li has published over 50 articles in top-tier journals, with more than 1000 citations and an H-index of 20. He is an External Expert at the National Center for Drug Evaluation, a member of multiple prestigious pharmacological committees, and a reviewer for leading journals such as Biomaterials and Clin Transl Med. His research focuses on personalized medicine, drug delivery systems, and epigenetic influences on pharmacodynamics.

Profile:

Orcid Profile

🏥 Current Positions:

Prof. Li Xingang serves as the Deputy Director of the Pharmacy Department at Beijing Friendship Hospital, where he is also the Chief Pharmacist. As a Professor and Ph.D. Supervisor, he is instrumental in nurturing future generations of pharmacists and researchers. His leadership role involves overseeing advanced pharmacological practices, mentoring young scientists, and ensuring cutting-edge drug evaluation and management systems. With a strong emphasis on precision medicine, Prof. Li combines clinical expertise and research excellence to address pressing healthcare challenges.

📚 Academic Background:

Prof. Li has an extensive academic background, which underpins his outstanding contributions to quantitative pharmacology and genetic pharmacology. His role as an External Expert at the National Center for Drug Evaluation and Review Expert for the Beijing Science and Technology Plan Project showcases his authority in the field. His memberships in prestigious committees, such as the Quantitative Pharmacology Committee of the Chinese Pharmacological Society and the Epigenetics Committee, reflect his deep commitment to advancing pharmaceutical sciences.

🧪 Research Interests and Achievements:

Quantitative Pharmacology: Prof. Li has a keen interest in developing predictive models to optimize drug efficacy and safety, leveraging mathematical frameworks to personalize treatment.

Genetic Pharmacology: His research focuses on exploring genetic factors that influence drug metabolism and efficacy, aiming to enhance personalized medicine approaches.

Prof. Li has successfully led over ten major projects, including initiatives funded by the Ministry of Science and Technology, the National Natural Science Foundation, and the Beijing Science and Technology Plan. These projects address critical areas like drug delivery systems, personalized pharmacotherapy, and genetic determinants of drug response.

🖋️ Publication Achievements:

Prof. Li’s academic rigor is evident in his extensive publication record, with over 50 articles in Q1 journals such as Nano Letters, Acta Pharmacologica Sinica, and Phytomedicine. His works have been cited more than 1000 times, and he holds an impressive H-index of 20, reflecting his impact on the scientific community. His publications explore innovative drug delivery systems, genetic biomarkers, and clinical pharmacokinetics, contributing significantly to global pharmacological advancements.

🏆 Scholarships and Awards:

Prof. Li has received numerous accolades for his contributions:

  • Servier Young Hospital Pharmacy Award, China Pharmaceutical Society
  • Outstanding Pharmacist Award, Beijing Pharmaceutical Society
  • Recognized for Outstanding Papers and groundbreaking research, reflecting his excellence in clinical pharmacy and translational research.

🧑‍🔬 Professional Associations and Editorial Roles:

Prof. Li is actively involved in professional organizations, including the Chinese Pharmacological Society and the China Pharmaceutical Education Association. He serves as an Editorial Board Member for journals such as China Hospital Pharmacy Evaluation and Analysis and Chinese Pharmacy, ensuring the dissemination of high-quality research.

As a Reviewer for prestigious journals like Biomaterials and Clin Transl Med, he evaluates cutting-edge studies in pharmacology, bioinformatics, and materials science, further contributing to his field’s knowledge base.

💻 Bioinformatics and Laboratory Experience:

Prof. Li integrates bioinformatics tools into his research to analyze complex datasets and identify genetic markers associated with drug response. His laboratory is equipped with advanced technologies for pharmacokinetic modeling, epigenetic profiling, and drug formulation analysis, enabling groundbreaking discoveries.

🎓 Training, Workshops, and Oral Presentations:

Prof. Li regularly participates in international conferences, presenting his research findings and engaging with global experts. His oral presentations at prestigious forums highlight advancements in therapeutic drug monitoring (TDM), anesthesiology pharmacy, and intravenous preparation management, solidifying his reputation as a thought leader.

✅ Tasks Completed as a Researcher:

Prof. Li has successfully completed tasks ranging from designing clinical trials to publishing high-impact research. His ability to translate laboratory findings into practical solutions for patient care exemplifies his commitment to improving healthcare outcomes.

🌟 Success Factors and Key Contributions:

Prof. Li’s success stems from his:

  • Collaborative approach in multidisciplinary projects
  • Innovative methodologies in drug evaluation and genetic research
  • Dedication to mentoring young professionals and fostering academic growth

🔬 Ongoing Research Projects:

His current projects delve into:

  • Advanced drug delivery systems to enhance treatment efficacy
  • Epigenetic influences on pharmacodynamics
  • Personalized medicine approaches using genetic profiling

🔍 Conclusion:

Prof. Li Xingang is a distinguished leader in the field of pharmacology, whose contributions span clinical excellence, innovative research, and impactful publications. His work in quantitative and genetic pharmacology, combined with his dedication to mentoring and professional engagement, sets him apart as a visionary in healthcare. His achievements and ongoing endeavors continue to shape the future of precision medicine and pharmacological sciences.

Top Notable Publications:

1. Immune-Related Colitis Induced by Camrelizumab: A Case Report

Authors: Xingang Li

Journal: Journal of Inflammation Research

Year: 2023

2. Population pharmacokinetics and dosing optimisation of imipenem in critically ill patients

Authors: Xingang Li

Journal: European Journal of Hospital Pharmacy: Science and Practice-

Year: 2023

3. Association of Alcohol Drinking and Helicobacter pylori Infection: A Meta-analysis

Authors: Xingang Li

Journal: Journal of Clinical Gastroenterology

Year: 2023

4. Population pharmacokinetics of oxcarbazepine 10-monohydroxy derivative in Chinese adult epileptic patients

Authors: Xingang Li

Journal: European Journal of Hospital Pharmacy: Science and Practice

Year: 2022

5. Association between GNAQ Gene DNA Methylation and Vascular Recurrence in Patients with Acute Ischemic Stroke or Transient Ischemic Attack

Authors: Xingang Li

Journal: Cerebrovascular Diseases (Basel, Switzerland)

Year: 2022

6. Impact of Azithromycin on Forsythiaside Pharmacokinetics in Rats: A Population Modeling Method

Authors: Xingang Li

Journal: Current Medical Science

Year: 2022

7. Docetaxel population pharmacokinetic modelling and simulation in Chinese cancer patients

Authors: Xingang Li

Journal: Annals of Translational Medicine

Year: 2022

8. Development of a multivariable clinical prediction model for liposomal doxorubicin-induced cardiotoxicity in adult breast cancer patients: A retrospective multicenter study

Authors: Xingang Li

Journal: Annals of Translational Medicine

Year: 2022

9. Population pharmacokinetics of methotrexate in pediatric patients with acute lymphoblastic leukemia and malignant lymphoma

Authors: Xingang Li

Journal: Xenobiotica

Year: 2022

10. The clinical population pharmacokinetics, metabolomics, and therapeutic analysis of alkaloids from Alstonia scholaris leaves in acute bronchitis patients

Authors: Xingang Li

Journal: Phytomedicine

Year: 2022